Hormonal therapy in cancer of the breast. V. The effect of methyltestosterone on clinical course and hormonal excretion

Segaloff, Albert; Horwitt, Benjamin N.; Carabasi, R. Anthony; Murison, Paul J.; Schlosser, Joseph V.

doi:10.1002/1097-0142(195305)6:3<483::aid-cncr2820060306>3.0.co;2-o

Cited by 29 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The major side effects of testolactone are gastro¬ intestinal (Segaloff et al 1960). Our patient had two episodes of diarrhoea, lasting 2 -3 days, during which testolactone was discontinued.…”

Section: Resultsmentioning

confidence: 99%

“…Agents that suppress pituitary secretion of gonadotrophins, such as the long-acting agonist of LRH, D-trp6-pro9-NEt-LRH, have also failed to achieve remission of menses and secondary sexual development (Foster et al 1984b;Comité et al 1981). We have treated a girl with McCune-Albright syndrome with the aromatase inhibitor, testolactone, which inhibits the conversion of androstenedione to oestrone and testoster¬ one to oestradiol (Segaloff et al 1960). Testolac¬ tone treatment was associated with cessation of menses, decreases in height velocity and the rate of bone age advancement, and suppression of plasma oestradiol levels.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Testolactone treatment of precocious puberty in McCune-Albright syndrome

Foster

Pescovitz

Comite

et al. 1985

Acta Endocrinologica

View full text Add to dashboard Cite

Current medical and surgical therapies of precocious puberty in McCune-Albright syndrome are often unsatisfactory. We used an aromatase inhibitor, testolactone, to treat precocious puberty in a girl with McCune-Albright syndrome. This child was unresponsive to 28 weeks of treatment with the long-acting agonist of LRH, D-trp6-pro9-NEt-LRH. During testolactone therapy, menses ceased, bone age advancement and height velocity diminished, and plasma oestradiol levels were suppressed. Serum gonadotrophin levels remained in the prepubertal range. Testolactone may be an effective therapy of precocious puberty in girls with McCune\x=req-\ Albright syndrome.Precocious puberty in girls with McCune-Albright syndrome is usually due to ovarian oestrogen secre¬ tion that is independent of pubertal hypothalamicpituitary activation. Previous attempts to treat the precocious puberty of McCune-Albright syndrome have met with limited success. Surgical wedge re¬ section of the ovaries or excision of ovarian cysts has resulted only in temporary remission of the symptoms of sexual precocity (Foster et al. 1984a; Scully & McNeely 1975). Agents that suppress pituitary secretion of gonadotrophins, such as the long-acting agonist of LRH, D-trp6-pro9-NEt-LRH, have also failed to achieve remission of menses and secondary sexual development (Foster et al. 1984b;Comité et al. 1981). We have treated a girl with McCune-Albright syndrome with the aromatase inhibitor, testolactone, which inhibits the conversion of androstenedione to oestrone and testoster¬ one to oestradiol (Segaloff et al. 1960). Testolac¬ tone treatment was associated with cessation of menses, decreases in height velocity and the rate of bone age advancement, and suppression of plasma oestradiol levels. Materials and Methods SubjectsThe patient, a 2 2/u year old girl, was the 2770 g product of a 24 year old G1 PO mother, who had an uncompli¬ cated pregnancy, labour, and delivery. The child devel¬ oped normally until she had an episode of vaginal bleeding at age 8 months. She continued to have periods every 4-6 weeks and was referred to the National Institutes of Health at the age of 15 months. There was no known exposure to oestrogens. The child's height was 82.5 cm (97th percentile). Height velocity between 11 and 15 months was 34.2 cm/year. (Height velocity of girls between 11 and 15 months is 13.5 ± 2.0 (SD) cm/year (Tanner 1965)). The weight was 10.6 kg (67th percen¬ tile), and the blood pressure was 90/60 mmHg. She had Tanner stage III breasts and no pubic hair. Her external genitalia were normal but her vaginal mucosa appeared oestrogenized and had a white mucoid discharge. The vaginal smear had 100% intermediate cells. There was no abnormal skin pigmentation. The remainder of the phy¬ sical examination was normal. Computed tomography of the head and ultrasonography of the adrenal glands showed no abnormalities. Pelvic ultrasound indicated a

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

Testolactone treatment of precocious puberty in McCune-Albright syndrome

Foster

Pescovitz

Comite

et al. 1985

Acta Endocrinologica

View full text Add to dashboard Cite

show abstract

“…X Segulofl et al 905 testosterone. 2 The changes in prolactin and luteinizing-hormone excretion were considered to be of no significance.…”

Section: Discussionmentioning

confidence: 99%

Hormonal therapy in cancer of the breast. X.The effect of vinyltestosterone therapy on clinical course and hormonal excretion

Segaloff

Gordon

Horwitt

et al. 1955

Cancer

Self Cite

View full text Add to dashboard Cite

“…Methyltestosterone can accomplish virtually all the actions of testosterone propionate and is a useful oral therapy (50). Chemical hepatitis (51), which may occur from methyltestosterone treatment, is an uncommon toxicity that is not prohibitive.…”

Section: Testosteronementioning

confidence: 99%

The Chemical Control of Cancer: PHR Review

Holland¹

1954

Public Health Reports (1896-1970)

View full text Add to dashboard Cite

Hormonal therapy in cancer of the breast. V. The effect of methyltestosterone on clinical course and hormonal excretion

Cited by 29 publications

References 7 publications

Testolactone treatment of precocious puberty in McCune-Albright syndrome

Testolactone treatment of precocious puberty in McCune-Albright syndrome

Hormonal therapy in cancer of the breast. X.The effect of vinyltestosterone therapy on clinical course and hormonal excretion

The Chemical Control of Cancer: PHR Review

Contact Info

Product

Resources

About